Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
galcanezumab
- Development stage
- Approved
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Galcanezumab is a humanized monoclonal antibody used for the prevention of migraine and the treatment of cluster headaches. It works by binding to and blocking calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathophysiology. By preventing CGRP from exerting its biological effects, galcanezumab helps reduce the frequency and severity of migraine attacks as well as episodic cluster headache attacks. The drug is administered via subcutaneous injection, typically once monthly. Galcanezumab was developed by Eli Lilly and received regulatory approval in 2018 in both the United States and European Union[2][3][5][6].
- Brand names
- Emgality
- Other names
- galcanezumab-gnlm
02
Targets
CGRP (Calcitonin gene-related peptide)
Beyond the preview
Go deeper on galcanezumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on galcanezumab.